Treatment of Neck and Upper Limb Pain Using BurstDR (De Ridder) Stimulation (NU-BURST)
Treatment of Neck and Upper (NU) Limb Pain Using BurstDR Stimulation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Lalit Venkatesan, Ph.D.
- Phone Number: +19723098522
- Email: LVenkatesan@sjm.com
Study Contact Backup
- Name: Filippo Agnesi, Ph.D.
- Phone Number: +19725264860
- Email: FAgnesi@sjm.com
Study Locations
-
-
-
Bristol, United Kingdom
- Southmead Hospital
-
London, United Kingdom
- Guy's St. Thomas Hospital
-
Southampton, United Kingdom
- University Hospital Southampton NHS Foundation Trust
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject is able to provide informed consent to participate in the study;
- Subject is 18 years of age or older;
- Subject has failed to respond to at least 6 months of conventional treatment which may include pharmacological treatment, physical therapy, and injections;
- Subject has failed to respond to medial branch blocks;
- Subject diagnosed with chronic predominant intractable neck pain with or without radiation down to arm/shoulder/upper back;
- Subject has neck pain intensity of at least 6.0 cm out of 10.0 cm on the average neck pain VAS at baseline (according to the last 3 days of the baseline pain diary);
- Subject is on stable pain medications with a total opioid equivalent of120 mg or less for at least 28 days prior to enrolling in this study, and is willing to stay on those medications with no dose increase until activation of the permanently implanted SCS device;
- Subject's medical record has been evaluated by the Investigator to ensure that the subject is a good candidate for a neurostimulation system;
- Subject is willing to cooperate with the study requirements including compliance with the regimen and completion of all office visits;
- Female candidates of child-bearing potential agree to commit to the use of an effective method of contraception (including but not limited to sterilization, barrier devices, oral contraceptives, intrauterine devices (IUDs), condoms, rhythm method, or abstinence) for the duration of the study
Exclusion Criteria:
- Subject has a current diagnosis of a coagulation disorder, bleeding diathesis, progressive peripheral vascular disease, moderate or severe cervical stenosis determined by existing or new MRI scan performed as part of standard of care, mechanical neck pain originating from cervical facet joint syndrome, post-herpetic neuralgia, spondylolisthesis, retrolisthesis, CRPS (Chronic Regional Pain Syndrome) or uncontrolled diabetes mellitus;
- Subject with significant scoliosis even if surgically corrected;
- Subject is currently participating in a clinical investigation that includes an active treatment arm;
- Subject has been implanted with or participated in a trial period for a neurostimulation system;
- Subject has an infusion pump;
- Subject has evidence of an active disruptive psychological or psychiatric disorder as determined as per standard of care;
- Subject has a current diagnosis of a progressive neurological disease as determined by the Investigator;
- Subject is immunocompromised;
- Subject has an existing medical condition that is likely to require repetitive MRI evaluation in the future (i.e. epilepsy, stroke, multiple sclerosis, acoustic neuroma, tumor);
- Subject has history of cancer requiring active treatment in the last 12 months;
- Subject has an existing medical condition that is likely to require the use of diathermy in the future;
- Subject has documented history of allergic response to titanium or silicone;
- Subject has a documented history of substance abuse (narcotics, alcohol, etc.) or substance dependency in the 6 months prior to baseline data collection;
- Subject is a female candidates of child bearing potential that are pregnant (confirmed by positive urine/blood pregnancy test);
- Subject has life expectancy of less than 1 year;
- Subject is involved in an injury claim under current litigation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: study patients
Single arm study.
Patients will receive Spinal Cord Stimulation (SCS) according to standard clinical procedures.
|
Implantation of SCS electrodes and stimulator according to clinical standards
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluate the change in pain intensity between baseline, trial and long-term follow up evaluations using Visual Analog Scale (VAS) assessments.
Time Frame: 3, 6 and 12 months
|
Golden standard self-evaluation of pain intensity
|
3, 6 and 12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
EQ-5D - 5L (European Quality of Life) (5D-dimensions); (5L levels)
Time Frame: baseline
|
Self reported questionnaire on quality of life
|
baseline
|
|
EQ-5D - 5L
Time Frame: End of SCS trial (up to two weeks after electrodes implantation)
|
Self reported questionnaire on quality of life
|
End of SCS trial (up to two weeks after electrodes implantation)
|
|
EQ-5D - 5L
Time Frame: 3 months post permanent implant
|
Self reported questionnaire on quality of life
|
3 months post permanent implant
|
|
EQ-5D - 5L
Time Frame: 6 months post permanent implant
|
Self reported questionnaire on quality of life
|
6 months post permanent implant
|
|
EQ-5D - 5L
Time Frame: 12 months post permanent implant
|
Self reported questionnaire on quality of life
|
12 months post permanent implant
|
|
ONDI
Time Frame: baseline
|
Disability questionnaire
|
baseline
|
|
ONDI (Oswestry neck disability index)
Time Frame: end of SCS trial (up to two weeks after electrodes implantation)
|
Disability questionnaire
|
end of SCS trial (up to two weeks after electrodes implantation)
|
|
ONDI
Time Frame: 3 months post permanent implant
|
Disability questionnaire
|
3 months post permanent implant
|
|
ONDI
Time Frame: 6 months post permanent implant
|
Disability questionnaire
|
6 months post permanent implant
|
|
ONDI
Time Frame: 12 months post permanent implant
|
Disability questionnaire
|
12 months post permanent implant
|
|
Patient Global Impression of Change
Time Frame: end of SCS trial (up to two weeks after electrodes implantation)
|
questionnaire on patient satisfaction with therapeutic outcome
|
end of SCS trial (up to two weeks after electrodes implantation)
|
|
Patient Global Impression of Change
Time Frame: 3 months post permanent implant
|
questionnaire on patient satisfaction with therapeutic outcome
|
3 months post permanent implant
|
|
Patient Global Impression of Change
Time Frame: 6 months post permanent implant
|
questionnaire on patient satisfaction with therapeutic outcome
|
6 months post permanent implant
|
|
Patient Global Impression of Change
Time Frame: 12 months post permanent implant
|
questionnaire on patient satisfaction with therapeutic outcome
|
12 months post permanent implant
|
|
Headache Impact Test
Time Frame: baseline
|
Questionnaire on headache burden
|
baseline
|
|
Headache Impact Test
Time Frame: end of SCS trial (up to two weeks after electrodes implantation)
|
Questionnaire on headache burden
|
end of SCS trial (up to two weeks after electrodes implantation)
|
|
Headache Impact Test
Time Frame: 3 months post permanent implant
|
Questionnaire on headache burden
|
3 months post permanent implant
|
|
Headache Impact Test
Time Frame: 6 months post permanent implant
|
Questionnaire on headache burden
|
6 months post permanent implant
|
|
Headache Impact Test
Time Frame: 12 months post permanent implant
|
Questionnaire on headache burden
|
12 months post permanent implant
|
|
Hospital Anxiety and Depression
Time Frame: baseline
|
Questionnaire on anxiety and depression
|
baseline
|
|
Hospital Anxiety and Depression
Time Frame: end of SCS trial (up to two weeks after electrodes implantation)
|
Questionnaire on anxiety and depression
|
end of SCS trial (up to two weeks after electrodes implantation)
|
|
Hospital Anxiety and Depression
Time Frame: 3 months post permanent implant
|
Questionnaire on anxiety and depression
|
3 months post permanent implant
|
|
Hospital Anxiety and Depression
Time Frame: 6 months post permanent implant
|
Questionnaire on anxiety and depression
|
6 months post permanent implant
|
|
Hospital Anxiety and Depression
Time Frame: 12 months post permanent implant
|
Questionnaire on anxiety and depression
|
12 months post permanent implant
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Adnan Al-Kaisy, MD, Guy's St. Thomas
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SJM-CIP-10194
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neck Pain
-
NCT07395011Not yet recruitingNeck Pain | Chronic Neck Pain | Neck Disability | Neck Pain Musculoskeletal | Neck Disease
-
NCT07605013RecruitingNonspecific Neck Pain | Neck Pain Musculoskeletal
-
NCT07260955Not yet recruitingChronic Neck Pain | Non-specific Neck Pain
-
NCT06635759Not yet recruitingChronic Neck Pain | Neck Pain Treatment | Neck Pain Chronic
-
NCT07266272CompletedNeck Pain | Mechanical Neck Pain | Pain Threshold | Cervical Pain, Posterior | Neck Pain Musculoskeletal | Extracorporeal Shock Wave Therapy
-
NCT07042230CompletedNeck Pain | Mechanical Neck Pain | Mobilization | Neck Pain Musculoskeletal | Proprioceptive Neuromuscular Facilitation
-
NCT05605132RecruitingNeck Pain | Cervical Pain | Neck Pain, Posterior | Neck Muscle Issue | Cervical Pain, Posterior
-
NCT05788263CompletedChronic Neck Pain | Persistent Neck Pain | Neuroscience Approach
-
NCT07190014Not yet recruiting
-
NCT07438548Completed
Clinical Trials on Spinal Cord Stimulation (SCS)
-
NCT06005584RecruitingParkinson Disease | Freezing of Gait
-
NCT03546738CompletedPain, Postoperative | Back Pain With Radiation
-
NCT00871819CompletedPain | Neuropathic Pain
-
NCT05373667Not yet recruiting
-
NCT03740763Terminated
-
NCT02741297Completed
-
NCT05466110RecruitingLow Back Pain | Spinal Fusion | Neuromodulation | Failed Back Surgery Syndrome | Spinal Cord Stimulation | SCS
-
NCT04894734RecruitingSpinal Cord Injury at T1-T12 Level | Traumatic Thoracic Spinal Cord Contusion | Thoracic Spinal Cord Trauma | Traumatic Thoracic Spinal Cord Laceration | Post-Traumatic Thoracic Myelopathy | Traumatic Thoracic Spinal Cord Myelopathy